TB/Micobactérias Não Tuberculosas
Impacto econômico da mortalidade por tuberculose em 120 países e o custo de não se atingir os Objetivos de Desenvolvimento Sustentável relacionados a tuberculose: uma análise de renda total.
12 Set, 2021 | 21:42hComentário convidado: The incalculable costs of tuberculosis
Comentários no Twitter
A strong eeconomic case for ending TB – trillions of dollars in savings. Cost of not acting now is going to be too expensive! @StopTB https://t.co/ffLVTeqOkj
— Suvanand Sahu (@SahuSuvanand) September 5, 2021
Failure to achieve the SDG tuberculosis mortality target by 2030 will lead to profound economic and health losses:
$3·0 trillion will be lost if the target is not met until 2045!!
Sachil Silva, Nim Pathy, @mikereidmd @DrEricGoosby @RifatAtun https://t.co/ipm5vj62IQ @LancetGH pic.twitter.com/fPHDW5eJWE
— Madhu Pai, MD, PhD (@paimadhu) September 3, 2021
Resumo | Recomendações da OMS para o tratamento da tuberculose resistente a medicamentos, atualização de 2020.
9 Jun, 2021 | 09:44hDiretriz original: WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment – Drug-Resistant Tuberculosis Treatment
Comentário no Twitter
🆕💥💥@ERSpublications
WHO guidelines on the treatment of drug-resistant TB contain the latest recommendations on shorter or longer all oral treatment regimens for patients with drug-resistant TB, including the medicines to be used& supportive measures https://t.co/qeeftVYdYN pic.twitter.com/4NKNNjz3Gh— Antibiotic Steward 🇵🇸💔Bassam Ghanem (@ABsteward) June 8, 2021
Mudança na prática | Um regime de 4 meses de rifapentina com moxifloxacina não é inferior ao regime padrão de 6 meses no tratamento da tuberculose.
6 Mai, 2021 | 07:34hComentário: Four-month TB treatment matches six-month standard of care – Aidsmap